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when CBT was assessed against SEGP, WMD was -12.2 (p0.024) at 4 months,
indicating that CBT (individualised therapy) demonstrated significantly better re-
duction in fatigue compared to SEGP (group therapy). CONCLUSIONS: Overall re-
sults demonstrated that CBT was significantly superior in alleviating fatigue com-
pared to no therapy, RT, and SEGP. CBT appears to be promising, acceptable and
clinically beneficial approach that could potentially benefit patients with MS fa-
tigue in future. Thus, further research is warranted to determine which aspects of
CBT are most effective and the optimal delivery of CBT for MS fatigue.
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OBJECTIVES: To report effects of BG-12 on the reduction in number of relapses
requiring intravenous steroids and multiple sclerosis (MS)-related hospitalizations
in DEFINE and CONFIRM, two Phase 3 studies of efficacy and safety of oral BG-12
(dimethyl fumarate) in patients with relapsing–remitting MS (RRMS). METHODS:
Patients aged 18–55 years with RRMS (McDonald criteria 2005) and an Expanded
Disability Status Scale score of 0–5.0 were randomized equally to oral BG-12 240 mg
twice (BID) or three times daily (TID) or placebo in DEFINE, or to oral BG-12 240 mg
BID or TID, placebo, or subcutaneous glatiramer acetate 20 mg/day (reference com-
parator) in CONFIRM. The primary endpoint at 2 years was: the proportion of pa-
tients relapsed in DEFINE, and annualized relapse rate in CONFIRM. Tertiary end-
points in both studies included number of relapses requiring intravenous steroid
therapy and MS-related hospitalizations. RESULTS: The intent-to-treat popula-
tions of the DEFINE and CONFIRM studies comprised 1,234 and 1,417 patients,
respectively. In DEFINE, BG-12 reduced the adjusted annualized rate of relapses
requiring steroids at 2 years by 52% (BID; rate ratio, 0.48 [95% confidence interval,
0.36–0.63]) and 51% (TID; 0.49 [0.37–0.64]) vs placebo (both p0.0001). Relative re-
ductions in CONFIRM were 44% (BID; 0.56 [0.42–0.76]) and 49% (TID; 0.51 [0.38–0.70])
vs placebo (p0.0002 and p0.0001). BG-12 also reduced the adjusted annualized
rate of MS-related hospitalizations at 2 years in DEFINE by 35% (BID; 0.65 [0.41–1.04])
and 45% (TID; 0.55 [0.34–0.88]) vs placebo (p0.0708 and p0.0125); relative reduc-
tions in CONFIRM were 32% (BID; 0.68 [0.42–1.09]) and 50% (TID; 0.50 [0.30–0.85]) vs
placebo (p0.1092 and p0.0098). CONCLUSIONS: These findings further support
the positive efficacy results for the primary and secondary clinical endpoints in
DEFINE and CONFIRM, and also suggest potential health economic benefits of
BG-12 treatment for relapsing MS.
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OBJECTIVES: To demonstrate the clinical effectiveness of capsaicin 8% patch
monotherapy in the treatment of post-herpetic neuralgia (PHN) using an integrated
analysis of individual patient data from Phase III studies. METHODS: Data from
four double-blind randomized controlled trials of patches containing either capsa-
icin 8% w/w (QTZ) or 0.04% capsaicin w/w (CTRL). Study subjects did not use con-
comitant neuropathic pain medication (either opioid, anticonvulsant, or antide-
pressant) during study period and received a 60-minute patch application. The
primary endpoint was percentage change in numeric pain rating scale (NPRS) “av-
erage pain for the past 24 hours” score between Baseline and Weeks 2-8 (week 12 as
secondary endpoint) following treatment. The proportion of subjects achieving a
30% decrease in their “average pain” NPRS scores from Baseline to Weeks 2–8
(“Responders”) was also analysed. The primary endpoint was analysed with a gen-
eral linear model with subject baseline characteristics and study allocation entered
as fixed effects and trial subgroup entered as a random effect. Statistical signifi-
cance for all tests was p0.05. RESULTS: A total of 533 subjects received capsaicin
monotherapy; 55% received QTZ. QTZ and CTRL subgroups had near-identical
baseline characteristics for gender (48% male), age (70.2 years); PHN duration (3.7
years), baseline “average” pain (5.5), and treatment area size (321cm2). The ad-
justed estimated marginal mean percentage change in pain from Baseline to Week
8 was -36.9% (95% CI: -40.9 to -32.0) for QTZ and -27.3 (-32.0 to -22.7) for CTRL
(p0.001). Baseline to Week 12 percentage change similarly favoured QTZ
(p0.001). At week 8, 52% of QTZ subjects were responders compared with 40% of
controls (p0.007). The adjusted odd-ratio for treatment response was 1.66 (95% CI:
1.15 to 2.40) in favour of QTZ. CONCLUSIONS: Capsaicin 8% patch monotherapy is
a clinically effective treatment option for post-herpetic neuralgia when compared
to low-dose active comparator.
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OBJECTIVES: To compare, in the absence of head-to-head trials, the clinical benefit
of gabapentin enacarbil, levodopa, pramipexole, ropinirole, and rotigotine in the
treatment of moderate-to-severe restless legs syndrome (RLS).METHODS:A mixed
treatment comparison (MTC) was performed using the Bayesian approach in the
software WinBUGS. A systematic literature review was first conducted to identify
RLS trials published over the past ten years through search on MEDLINE, EMBASE,
Cochrane CENTRAL and manufacturers’ websites. Twenty-eight clinical trials were
retained after two screenings. To minimize heterogeneity on dosing and trial du-
ration, a smaller set of fifteen trials were included in the primary analysis, com-
prising 4,413 patients. A sensitivity analysis was then performed on the full set of
twenty-eight trials to validate the results of the primary analysis. RESULTS: The
indirect comparison was established among four active treatments (gabapentin
enacarbil, pramipexole, ropinirole, rotigotine) and placebo, due to the lack of latest
clinical evidence on levodopa. Analysis on the primary endpoints indicates that
rotigotine is most likely to lead to the greatest reduction in IRLS score from baseline
(probability of 64.7% at the end of maintenance, and of 70.6% at week 12). Rotigo-
tine’s comparative therapeutic benefit is also observed in IRLS responders rate and
in five out of six items of the RLS-6 scale. CONCLUSIONS: Based on the results of
this MTC, rotigotine is most likely the most efficacious treatment option to alleviate
RLS symptoms. Head-to-head clinical trials should be conducted to confirm the
findings of this MTC.
PND6
COMBINING RCT AND OBSERVATIONAL DATA IN A MIXED TREATMENT
COMPARISON OF DISEASE-MODIFYING-THERAPIES FOR MULTIPLE SCLEROSIS
Fogarty E1, Schmitz S2, Walsh C3, Barry M4
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin,
Dublin, Ireland, 3Trinity College Dublin, Dublin, Ireland, 4St. James’s Hospital, Dublin, Ireland,
Ireland
OBJECTIVES: The advent of new, costly disease-modifying-therapies (DMT) for
multiple sclerosis (MS) requires consideration of all evidence on comparative ef-
fectiveness with existing therapies to inform both health policy and clinical care.
This study compares the relative effectiveness of DMTs within a mixed treatment
comparison (MTC) framework, and explores the contribution of real-world evi-
dence from observational studies to the evidence-base. METHODS: Sixteen ran-
domised controlled trials (RCTs) and four observational studies incorporating nine
DMTs were identified according to specified inclusion criteria following a system-
atic review of the literature. A Bayesian MTC model was fitted in WinBUGS, for the
outcome Annualised Relapse Rate (ARR). Alternative methods of combining data
from different trial designs were used. The model was extended to a meta-regres-
sion to include baseline covariates. RESULTS: Natalizumab and Fingolimod, two
recently approved DMTs, were significantly more effective than other DMTs for the
ARR outcome versus placebo, while the least effective option was Interferon be-
ta-1a 6MIU. Minimal differences were observed among the other DMTs. Baseline
covariates had no significant impact on the results. Observational data was avail-
able only for the older DMTs. An MTC of these trials supported the ranking in
effectiveness obtained from the RCT MTC, although individual estimates of effec-
tiveness were different to RCT estimates and uncertainty was substantial. As an
alternative to naïve pooling of both RCT and observational data, utilising the ob-
servational data as prior information allowed for adjustment of bias due to trial
design. CONCLUSIONS: Relative clinical effectiveness of DMTs is an important
component in the assessment of cost-effectiveness of these agents. RCTs provide
the foundation for evaluating comparative effectiveness of DMTs. However, obser-
vational studies can contribute complementary evidence on important compara-
tive effectiveness questions.
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OBJECTIVES: This study aimed to analyse the pattern of prescription and use of
antiepileptic drugs (AEDs), being its main focuses the characterization of off-label
use and its costs. METHODS: Cross sectional survey, carried out from Sept. 2009 to
Feb. 2010 in 20 pharmacies of Lisbon Region. Inclusion criteria: pharmacy users with
a prescription including at least 1 AED (all medicines listed under the Anatomical
Therapeutic Chemical code N03-Antiepileptics, having epilepsy in the SPC as main
indication). Information was collected by interview, conducted by trained phar-
macy students based on self-reported data. Prescription expenditures were ob-
tained by crossing the official price of each medicine single unit, at the time of the
study, with data on posology reported by each patient. Aggregate annual expendi-
tures were calculated based on that information. RESULTS: Data from 543 patients
was analyzed (61.3% females), age range 2-91 years (mean: 50.9). The main con-
sumed AEDs were valproic acid (18.0%), pregabalin (16.2%), topiramate (15.7%) and
carbamazepine (14.7%). The first prescriber was in 36.1% of the cases a neurologist
and in 31.9% a psychiatrist. Epilepsy was the indication in 29.5% of the patients.
Off-label use was found in 33.1% of the sample. Among the off-label sample, topi-
ramate (28.2%), clonazepam (17.2%), valproic acid (16.7%) and gabapentine (10.9%)
were the anticonvulsants most widely used off-label. Clonazepam (85.7%) and topi-
ramate (59.0%) had most of their uses in off-label indications. Psychiatrists (59.2%)
were the prescribers in the majority of the off-label cases. The main off-label indi-
cations were depression (31.4%) and mood stabilization (19.4%). Total costs with
AEDs were 210,851.57€ in which 48,424.04€ (23.0%) represents an off-label cost.
CONCLUSIONS: Approximately 1/3 of the sample used AEDs in off-label indica-
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